“`html
Biotech Business Loans: Funding Your Lab, R&D & Operations (2026)
Yes — you can get a loan for your biotech company. Whether you’re a pre-revenue startup or a growth-stage life sciences firm, multiple funding paths exist specifically for biotech operations. SBA 7(a) loans go up to $5 million and work for biotech companies with demonstrated traction. Lab equipment financing covers bioreactors, sequencers, centrifuges, and imaging systems at rates between 6% and 15%, often with the equipment itself as collateral. R&D lines of credit let you draw against ongoing research costs as needed. Revenue-based financing is available even for pre-revenue biotech companies with SBIR grants or signed LOIs. The right loan depends on your stage, your assets, and what the capital is for — this guide breaks down every option with the numbers that matter.
What Biotech Businesses Can Borrow For
Biotech financing isn’t one-size-fits-all. Lenders and programs are structured around specific use cases — and matching your need to the right loan type dramatically improves approval odds and terms.
- Lab equipment purchases: Bioreactors, flow cytometers, gene sequencers, centrifuges, biosafety cabinets, and imaging systems. Equipment financing uses the asset as collateral, making it accessible even for early-stage companies. → Best fit: Equipment financing or SBA 7(a)
- R&D operations and consumables: Reagents, culture media, lab supplies, CRO contracts, and outsourced testing. Recurring costs like these are well-suited to revolving lines of credit. → Best fit: R&D line of credit, working capital loan
- Clinical trial costs: Phase I/II trials, patient recruitment, trial management software, and CRO fees. These are large, milestone-based expenditures. → Best fit: SBA 7(a), venture debt, milestone-based credit facility
- FDA compliance and regulatory submissions: 510(k) prep, IND applications, GMP facility upgrades, and quality management systems. → Best fit: SBA 7(a), working capital loan
- Hiring scientific and operational staff: Scientists, regulatory specialists, lab managers. Payroll-focused working capital loans cover hiring ramps. → Best fit: Working capital loan, SBA 7(a)
- Bridge financing between funding rounds: Covering operating expenses between Series A and Series B, or while an SBIR grant is processing. → Best fit: Revenue-based financing, venture debt, bridge line of credit
- Facility leasehold improvements: Buildout of GMP suites, cleanrooms, or BSL-2 labs. → Best fit: SBA 504, SBA 7(a)
Biotech Loan Options: Side-by-Side Comparison
Use this table to quickly identify which structure fits your current stage and funding need.
| Loan Type | Typical Amount | Rate Range | Term | Best For |
|---|---|---|---|---|
| Equipment Financing | $10K – $2M+ | 6% – 15% | 2 – 7 years | Buying or leasing lab instruments; equipment serves as collateral, reducing qualification barriers |
| SBA 7(a) Loan | Up to $5M | Prime + 2.75% – 4.75% | 10 – 25 years | Established biotech companies funding operations, hiring, facility improvements, or clinical costs |
| Working Capital Loan | $25K – $500K | 8% – 35% | 6 months – 5 years | Covering payroll, consumables, and short-term operating gaps for revenue-generating biotech firms |
| R&D Line of Credit | $50K – $1M | 7% – 20% | Revolving (12-month draw periods) | Ongoing research expenses, CRO contracts, and milestone-based spending that fluctuates month to month |
| Revenue-Based Financing | $25K – $2M | Factor rate 1.1 – 1.5x | 6 – 36 months | Pre-revenue or early-revenue biotech with SBIR grants, licensing royalties, or signed contracts |
Rates and amounts vary by lender, credit profile, and business financials. Use the comparison tool below to see real offers for your company.
What Biotech Lenders Actually Look For
Biotech lending eligibility differs significantly from standard small business lending. Lenders who understand life sciences evaluate a different risk profile than a retail or restaurant lender would.
IP portfolio and patent status: Issued patents, patent-pending applications, and exclusive licenses are treated as collateral or value-generating assets by many biotech-focused lenders. A strong IP position can offset limited revenue history.
Grant funding history: SBIR Phase I and Phase II awards signal federal validation of your science. Many lenders view a Phase II SBIR (up to $2M) as equivalent to a funding milestone. STTR grants carry similar weight.
Burn rate and runway: Lenders want to see that your current capital extends at least 12 months, or that the loan proceeds bridge you to a defined next milestone (trial completion, IND submission, next funding round).
Revenue stage: Pre-revenue companies aren’t automatically disqualified — but lenders will shift to asset-based or grant-backed underwriting. Revenue-generating biotech companies (from licensing, services, or product sales) have access to a much broader lender pool.
Management team credentials: PhDs, MDs, and industry-experienced executives meaningfully improve approval odds with life sciences lenders. Your team’s track record matters.
Minimum typical requirements for most biotech loans:
- 1+ years in business (2+ for SBA)
- 600+ personal credit score (680+ preferred for SBA)
- $100K+ annual revenue (or equivalent grant funding for alternative lenders)
- U.S.-based legal entity (C-corp, LLC, or LP)
SBA Loans for Biotech Companies: How It Works
The SBA 7(a) loan program is one of the most powerful financing tools available to life sciences companies — but it’s underused because many biotech founders assume they won’t qualify. Here’s what you need to know.
How the SBA 7(a) works for biotech: The SBA doesn’t lend directly. It guarantees up to 85% of loans made by approved lenders, which reduces the lender’s risk and unlocks better terms for borrowers. For biotech companies, this means access to longer repayment terms (up to 10 years for working capital, 25 years for real estate) and lower rates than conventional alternatives.
What biotech companies use SBA 7(a) for: Equipment purchases, leasehold improvements to lab space, hiring and payroll, regulatory compliance costs, clinical development expenses, and working capital. It is a general-purpose loan — which makes it unusually flexible for the varied cost structure of a biotech company.
SBA 7(a) size and rate: Up to $5 million. Rates are variable, tied to the prime rate plus a lender spread (typically 2.75% to 4.75% depending on loan size and term). As of 2026, all-in rates are generally in the 10%–13% range.
The SBA 504 for facility and equipment: If you’re purchasing a GMP facility, building out a cleanroom, or buying major capital equipment, the SBA 504 loan offers up to $5.5 million at fixed rates with as little as 10% down. For capital-intensive biotech build-outs, this is often a better fit than 7(a).
Key challenge: SBA loans require 2 years in business, profitability (or a clear path to it), and personal guarantees from owners with 20%+ equity. Pre-revenue startups will need to look at SBIR grants, equipment financing, or revenue-based options first — then revisit SBA once operational history is established.
Revenue-Based Financing for Pre-Revenue Biotech
Most pre-revenue biotech companies assume debt financing is off the table. Revenue-based financing (RBF) changes that calculation — and it’s increasingly structured specifically for life sciences companies.
How RBF works: Instead of fixed monthly payments, you repay a percentage of monthly revenue (or incoming cash flows) until a fixed repayment cap is reached. If revenue is low one month, your payment is lower. If you close a licensing deal or receive a grant disbursement, repayment accelerates.
What qualifies as “revenue” for biotech RBF: SBIR/STTR grant disbursements, NIH or DOD contract payments, licensing royalties, fee-for-service lab revenue, and signed milestone payments from pharma partnerships can all be counted as qualifying cash flow by non-dilutive RBF lenders.
Typical terms: $25K to $2M, factor rates of 1.1x to 1.5x the borrowed amount, repayment periods of 6–36 months. No equity is given up — making this a genuinely non-dilutive option at a stage where dilution is most expensive.
Best use case: Bridging between SBIR Phase I and Phase II, covering operating costs while awaiting a Series A close, or funding a specific milestone without opening a full funding round.
How to Apply for a Biotech Business Loan
The application process for biotech financing is more involved than a standard small business loan — but breaking it into four steps makes it manageable.
Step 1: Define Your Capital Need Precisely
Know the exact dollar amount, what it’s for, and how it connects to a specific milestone (trial completion, IND submission, product launch, next funding round). Lenders — especially biotech-savvy ones — respond well to milestone-linked loan requests. Vague “working capital” requests get lower approval rates and worse terms.
Step 2: Gather Your Documentation Package
For most biotech loans, prepare the following:
- 2 years of business tax returns (or YTD P&L if under 2 years old)
- 3–6 months of business bank statements
- IP portfolio summary or patent list
- Grant award letters (SBIR, NIH, DARPA, etc.)
- Current cap table (for VC-backed companies)
- Use of funds statement tied to milestones
- Personal financial statements for owners with 20%+ equity
Step 3: Match Loan Type to Your Stage
Pre-revenue with grants → start with equipment financing or RBF. Early revenue with 1–2 years of operating history → SBA 7(a) or working capital loan. Scaling company with lab infrastructure → SBA 504 or equipment refinance. Bridging between rounds → R&D line of credit or RBF.
Step 4: Compare Multiple Lenders Before Committing
Biotech lending is a specialty market. Rates and terms vary significantly between lenders, and not all lenders understand life sciences risk profiles. Using a marketplace that matches you to biotech-friendly lenders without a hard credit pull protects your score while giving you real options to compare.
Frequently Asked Questions: Biotech Business Loans
Can a pre-revenue biotech startup get a business loan?
Yes, but your options are more limited than a revenue-generating company. The strongest path for pre-revenue biotech startups is equipment financing (where the lab equipment itself serves as collateral), revenue-based financing backed by SBIR grant disbursements or contract payments, and SBIR/STTR grants themselves — which are non-dilutive and function like grant-funded working capital. Traditional bank loans and SBA loans typically require at least one to two years of operating history and some form of revenue. If you are pre-revenue, focus on matching your loan type to your available collateral or cash flow (grants, contracts, LOIs) rather than trying to qualify for a conventional loan product you’re not yet positioned for.
Does having VC backing help or hurt when applying for a biotech loan?
It helps — with the right lenders. Venture-backed biotech companies are well-positioned for venture debt, which is specifically designed as a complement to equity financing. Lenders offering venture debt — Silicon Valley Bank (now part of First Citizens), Hercules Capital, Western Technology Investment, and others — view a strong VC syndicate as validation of the company’s risk profile. However, conventional SBA lenders and community banks may view a VC-backed cap table as complex or unfamiliar. The key is matching your capital structure to the right lender type. If you have institutional investors, venture debt is almost always worth exploring before pursuing SBA or conventional working capital loans.
What’s the difference between a biotech business loan and SBIR funding?
SBIR (Small Business Innovation Research) grants are non-dilutive, non-repayable federal awards that fund R&D at Phase I (up to ~$275K) and Phase II (up to ~$2M) levels. They are not loans — there is no repayment obligation. Business loans, by contrast, are borrowed capital that must be repaid with interest. SBIR and business loans are not mutually exclusive and are frequently used together: SBIR funds core R&D, while business loans cover equipment, hiring, facility costs, and operations not covered by the grant. Many biotech-focused lenders view SBIR award history as positive underwriting criteria, and some lenders will specifically lend against the future disbursement of an awarded SBIR grant.
What credit score do I need for a biotech business loan?
It depends on the loan type. Equipment financing is the most accessible, with some lenders approving at 600+ if the equipment value supports the loan amount. SBA 7(a) loans generally require a personal credit score of 680 or higher, though some SBA lenders will go to 650 with compensating factors like strong cash flow or significant collateral. Revenue-based financing and working capital loans from online lenders often work with scores as low as 600–620 but charge higher rates for lower scores. If your personal credit score is below 640, prioritize equipment financing and RBF while working to improve your score before applying for SBA or bank products. Business credit history, time in business, and cash flow can partially offset a lower personal score in some lending programs.
How long does it take to get a biotech business loan funded?
Funding timelines vary significantly by loan type. Equipment financing and online working capital loans can fund in as little as 2–5 business days once documentation is complete. Revenue-based financing from specialty lenders typically takes 1–2 weeks. SBA 7(a) loans are the slowest, averaging 30–90 days from application to funding depending on the lender’s SBA approval process — though SBA Preferred Lenders (who can approve internally) can sometimes compress this to 3–4 weeks. If you are bridging between funding rounds or facing a time-sensitive milestone deadline, lead time on your loan application matters enormously. Apply at least 60–90 days before you need the capital for SBA loans; 2–4 weeks for equipment and RBF products. Starting the application process before you are in urgent need gives you negotiating leverage and better terms.
“`